MAGE-A antigens as targets in tumour therapy

Cancer Letters

Volumn 324, Issue 2, 2012, Pages 126-132

  Meek, David W ^a   Marcar, Lynnette ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Drug targets; MAGE A; Melanoma antigen; RING finger proteins; Transcription factors

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CANCER VACCINE; MELANOMA ANTIGEN; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 2; MELANOMA ANTIGEN 3; MELANOMA ASSOCIATED ANTIGEN A; MELANOMA ASSOCIATED ANTIGEN A11; MELANOMA ASSOCIATED ANTIGEN C2; MELANOMA ASSOCIATED ANTIGEN G1; PROTEIN KAP1; PROTEIN MDM2; PROTEIN P53; REPRESSOR PROTEIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CRYSTAL STRUCTURE; DRUG TARGETING; GENE EXPRESSION PROFILING; HODGKIN DISEASE; HUMAN; LUNG NON SMALL CELL CANCER; MELANOMA ASSOCIATED ANTIGEN A GENE; MELANOMA ASSOCIATED ANTIGEN GENE; MYELODYSPLASTIC SYNDROME; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SHORT SURVEY; STRUCTURE ACTIVITY RELATION; TRANSCRIPTION REGULATION;

EID: 84864380076     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.05.011     Document Type: Review

References (48)

1. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B., Knuth A., Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991, 254:1643-1647.
2. Chomez P., De Backer O., Bertrand M., De Plaen E., Boon T., Lucas S. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res. 2001, 61:5544-5551.
3. Simpson A.J., Caballero O.L., Jungbluth A., Chen Y.T., Old L.J. Cancer/testis antigens, gametogenesis and cancer. Nat. Rev. Cancer 2005, 5:615-625.
4. Liu W., Cheng S., Asa S.L., Ezzat S. The melanoma-associated antigen A3 mediates fibronectin-controlled cancer progression and metastasis. Cancer Res. 2008, 68:8104-8112.
5. Wilson E.M. Androgen receptor molecular biology and potential targets in prostate cancer. Ther. Adv. Urol. 2010, 2:105-117.
6. Doyle J.M., Gao J., Wang J., Yang M., Potts P.R. MAGE-RING protein complexes comprise a family of E3 ubiquitin ligases. Mol. Cell 2010, 39:963-974.
7. Gjerstorff M.F., Harkness L., Kassem M., Frandsen U., Nielsen O., Lutterodt M., Mollgard K., Ditzel H.J. Distinct GAGE and MAGE-A expression during early human development indicate specific roles in lineage differentiation. Hum. Reprod. 2008, 23:2194-2201.
8. Sang M., Wang L., Ding C., Zhou X., Wang B., Lian Y., Shan B. Melanoma-associated antigen genes - an update. Cancer Lett. 2011, 302:85-90.
9. Scanlan M.J., Gure A.O., Jungbluth A.A., Old L.J., Chen Y.T. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol. Rev. 2002, 188:22-32.
10. Yang B., O'Herrin S.M., Wu J., Reagan-Shaw S., Ma Y., Bhat K.M., Gravekamp C., Setaluri V., Peters N., Hoffmann F.M., Peng H., Ivanov A.V., Simpson A.J., Longley B.J. MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. Cancer Res. 2007, 67:9954-9962.
11. Duan Z., Duan Y., Lamendola D.E., Yusuf R.Z., Naeem R., Penson R.T., Seiden M.V. Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines. Clin. Cancer Res. 2003, 9:2778-2785.
12. Kasuga C., Nakahara Y., Ueda S., Hawkins C., Taylor M.D., Smith C.A., Rutka J.T. Expression of MAGE and GAGE genes in medulloblastoma and modulation of resistance to chemotherapy. Laboratory investigation. J. Neurosurg. Pediatr. 2008, 1:305-313.
13. Monte M., Simonatto M., Peche L.Y., Bublik D.R., Gobessi S., Pierotti M.A., Rodolfo M., Schneider C. MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc. Natl. Acad. Sci. USA 2006, 103:11160-11165.
14. Weeraratne S.D., Amani V., Neiss A., Teider N., Scott D.K., Pomeroy S.L., Cho Y.J. MiR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma. Neuro Oncol. 2011, 13:165-175.
15. Park J.H., Kong G.H., Lee S.W. HMAGE-A1 overexpression reduces TNF-alpha cytotoxicity in ME-180 cells. Mol. Cells 2002, 14:122-129.
16. De Smet C., Courtois S.J., Faraoni I., Lurquin C., Szikora J.P., De Backer O., Boon T. Involvement of two Ets binding sites in the transcriptional activation of the MAGE1 gene. Immunogenetics 1995, 42:282-290.
17. De Smet C., Lurquin C., Lethe B., Martelange V., Boon T. DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol. Cell. Biol. 1999, 19:7327-7335.
18. Wischnewski F., Pantel K., Schwarzenbach H. Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells. Mol. Cancer Res. 2006, 4:339-349.
19. Zhu X., Asa S.L., Ezzat S. Fibroblast growth factor 2 and estrogen control the balance of histone 3 modifications targeting MAGE-A3 in pituitary neoplasia. Clin. Cancer Res. 2008, 14:1984-1996.
20. Barker P.A., Salehi A. The MAGE proteins: emerging roles in cell cycle progression, apoptosis, and neurogenetic disease. J. Neurosci. Res. 2002, 67:705-712.
21. Kondo T., Zhu X., Asa S.L., Ezzat S. The cancer/testis antigen melanoma-associated antigen-A3/A6 is a novel target of fibroblast growth factor receptor 2-IIIb through histone H3 modifications in thyroid cancer. Clin. Cancer Res. 2007, 13:4713-4720.
22. Guerineau M., Kriz Z., Kozakova L., Bednarova K., Janos P., Palecek J. Analysis of the Nse3/MAGE-binding domain of the Nse4/EID family proteins. PLoS One 2012, 7:e35813.
23. Hudson J.J., Bednarova K., Kozakova L., Liao C., Guerineau M., Colnaghi R., Vidot S., Marek J., Bathula S.R., Lehmann A.R., Palecek J. Interactions between the Nse3 and Nse4 components of the SMC5-6 complex identify evolutionarily conserved interactions between MAGE and EID families. PLoS One 2011, 6:e17270.
24. Salehi A.H., Roux P.P., Kubu C.J., Zeindler C., Bhakar A., Tannis L.L., Verdi J.M., Barker P.A. NRAGE, a novel MAGE protein, interacts with the p75 neurotrophin receptor and facilitates nerve growth factor-dependent apoptosis. Neuron 2000, 27:279-288.
25. Jordan B.W., Dinev D., LeMellay V., Troppmair J., Gotz R., Wixler L., Sendtner M., Ludwig S., Rapp U.R. Neurotrophin receptor-interacting mage homologue is an inducible inhibitor of apoptosis protein-interacting protein that augments cell death. J. Biol. Chem. 2001, 276:39985-39989.
26. Saburi S., Nadano D., Akama T.O., Hirama K., Yamanouchi K., Naito K., Tojo H., Tachi C., Fukuda M.N. The trophinin gene encodes a novel group of MAGE proteins, magphinins, and regulates cell proliferation during gametogenesis in the mouse. J. Biol. Chem. 2001, 276:49378-49389.
27. Taniura H., Matsumoto K., Yoshikawa K. Physical and functional interactions of neuronal growth suppressor necdin with p53. J. Biol. Chem. 1999, 274:16242-16248.
28. Laduron S., Deplus R., Zhou S., Kholmanskikh O., Godelaine D., De Smet C., Hayward S.D., Fuks F., Boon T., De Plaen E. MAGE-A1 interacts with adaptor SKIP and the deacetylase HDAC1 to repress transcription. Nucleic Acids Res. 2004, 32:4340-4350.
29. Xiao T.Z., Bhatia N., Urrutia R., Lomberk G.A., Simpson A., Longley B.J. MAGE I transcription factors regulate KAP1 and KRAB domain zinc finger transcription factor mediated gene repression. PLoS One 2011, 6:e23747.
30. Feng Y., Gao J., Yang M. When MAGE meets RING: insights into biological functions of MAGE proteins. Protein Cell 2011, 2:7-12.
31. Marcar L., Maclaine N.J., Hupp T.R., Meek D.W. Mage-A cancer/testis antigens inhibit p53 function by blocking its interaction with chromatin. Cancer Res. 2010, 70:10362-10370.
32. Aprelikova O., Pandolfi S., Tackett S., Ferreira M., Salnikow K., Ward Y., Risinger J.I., Barrett J.C., Niederhuber J. Melanoma antigen-11 inhibits the hypoxia-inducible factor prolyl hydroxylase 2 and activates hypoxic response. Cancer Res. 2009, 69:616-624.
33. Nardiello T., Jungbluth A.A., Mei A., Diliberto M., Huang X., Dabrowski A., Andrade V.C., Wasserstrum R., Ely S., Niesvizky R., Pearse R., Coleman M., Jayabalan D.S., Bhardwaj N., Old L.J., Chen-Kiang S., Cho H.J. MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of survivin. Clin. Cancer Res. 2011, 17:4309-4319.
34. Peche L.Y., Scolz M., Ladelfa M.F., Monte M., Schneider C. MageA2 restrains cellular senescence by targeting the function of PMLIV/p53 axis at the PML-NBs. Cell Death Differ. 2012, 19:926-936.
35. Friedman J.R., Fredericks W.J., Jensen D.E., Speicher D.W., Huang X.P., Neilson E.G., Rauscher F.J. KAP-1, a novel corepressor for the highly conserved KRAB repression domain. Genes Dev. 1996, 10:2067-2078.
36. Kim S.S., Chen Y.M., O'Leary E., Witzgall R., Vidal M., Bonventre J.V. A novel member of the RING finger family, KRIP-1, associates with the KRAB-A transcriptional repressor domain of zinc finger proteins. Proc. Natl. Acad. Sci. USA 1996, 93:15299-15304.
37. Moosmann P., Georgiev O., Le Douarin B., Bourquin J.P., Schaffner W. Transcriptional repression by RING finger protein TIF1 beta that interacts with the KRAB repressor domain of KOX1. Nucleic Acids Res. 1996, 24:4859-4867.
38. Wang C., Ivanov A., Chen L., Fredericks W.J., Seto E., Rauscher F.J., Chen J. MDM2 interaction with nuclear corepressor KAP1 contributes to p53 inactivation. EMBO J. 2005, 24:3279-3290.
39. Meek D.W. Tumour suppression by p53: a role for the DNA damage response?. Nat. Rev. Cancer 2009, 9:714-723.
40. Brichard V.G., Lejeune D. GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development. Vaccine 2007, 25(Suppl. 2):B61-B71.
41. Brichard V.G., Lejeune D. Cancer immunotherapy targeting tumour-specific antigens: towards a new therapy for minimal residual disease. Expert Opin. Biol. Ther. 2008, 8:951-968.
42. Goldman B., DeFrancesco L. The cancer vaccine roller coaster. Nat. Biotechnol. 2009, 27:129-139.
43. Mellstedt H., Vansteenkiste J., Thatcher N. Vaccines for the treatment of non-small cell lung cancer: investigational approaches and clinical experience. Lung Cancer 2011, 73:11-17.
44. Goodyear O., Agathanggelou A., Novitzky-Basso I., Siddique S., McSkeane T., Ryan G., Vyas P., Cavenagh J., Stankovic T., Moss P., Craddock C. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood 2010, 116:1908-1918.
45. Cruz C.R., Gerdemann U., Leen A.M., Shafer J.A., Ku S., Tzou B., Horton T.M., Sheehan A., Copeland A., Younes A., Rooney C.M., Heslop H.E., Bollard C.M. Improving T-cell therapy for relapsed EBV-negative hodgkin lymphoma by targeting upregulated MAGE-A4. Clin. Cancer Res. 2011, 17:7058-7066.
46. Joseph T.L., Lane D., Verma C.S. Stapled peptides in the p53 pathway: computer simulations reveal novel interactions of the staples with the target protein. Cell Cycle 2010, 9:4560-4568.
47. Vassilev L.T. MDM2 inhibitors for cancer therapy. Trends Mol. Med. 2007, 13:23-31.
48. Bhatia N., Yang B., Xiao T.Z., Peters N., Hoffmann M.F., Longley B.J. Identification of novel small molecules that inhibit protein-protein interactions between MAGE and KAP-1. Arch. Biochem. Biophys. 2011, 508:217-221.